Clinical Trial

GD2-CAR T Cells for Pediatric Brain Tumours

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the safety and efficacy of iC9-GD2-CAR T-cells, a third generation (4.1BB-CD28) CAR T cell treatment targeting GD2 in paediatric or young adult patients affected by relapsed/refractory malignant central nervous system (CNS) tumors. In order to improve the safety of the approach, the suicide gene inducible Caspase 9 (iC9) has been included.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-03-18; most recent amendment 2025-02-03.
Status change: Not Yet Recruiting → Recruiting 2023-11-16
Trial Details
NCT Number NCT05298995
Lead Sponsor Bambino Gesù Hospital and Research Institute
Conditions Brain Tumor, Pediatric, Medulloblastoma, Childhood, Embryonal Tumor, High Grade Glioma, Diffuse Midline Glioma, Diffuse Intrinsic Pontine Glioma, Brain Tumor Adult
Enrollment 54 participants
Start Date 2023-11-09
Primary Completion 2027-11 (estimated)
Study Completion 2038-11 (estimated)
Updated on ClinicalTrials.gov 2025-02-05